RecallRadar

FDA Device recall Z-1038-2024

BD BBL Sensi Disc Rifampin- 5 ug, used for semi-quantitative in vitro susceptibility testing

On 2024-02-14 the FDA classified a Class II recall of BD BBL Sensi Disc Rifampin- 5 ug, used for semi-quantitative in vitro susceptibility testing by Becton Dickinson And, citing there is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed resul….

Read the official FDA Device notice

AgencyFDA Device
Recall numberZ-1038-2024
ClassificationClass II
Statusongoing
Initiated2024-01-08
Published2024-02-14
Last updated2026-09-13 11:57 UTC
CompanyBecton Dickinson And
DistributionUS

Product

BD BBL Sensi Disc Rifampin- 5 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231541 and 231544¿

Reason

There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.

Identifiers

code_info
Catalog No. 231541 UDI-DI 00382902315414 Lots 1278110 1334479 2004554 2025125 2056466 2242510 3214931; Catalog No. 231…Catalog No. 231541 UDI-DI 00382902315414 Lots 1278110 1334479 2004554 2025125 2056466 2242510 3214931; Catalog No. 231544¿ UDI-DI 30382902315446 Lots 1116055 1211489 2339407 3030278 3158059 3214931 0343413 1032232 1088790 1148547 1278110 1334479 2004554 2025125 2056466 2090443 2242510

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:57 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/device/enforcement.json?search=recall_number:%22Z-1038-2024%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.